Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are central mediators of cardiac hypertrophy and are discussed as potential therapeutic targets. However, direct inhibition of ERK1/2 leads to exacerbated cardiomyocyte death and impaired heart function. We have previously identified ERK Thr188 autophosphorylation as a regulatory phosphorylation of ERK1/2 that is a key factor in cardiac hypertrophy. Here, we investigated whether interference with ERK Thr188 phosphorylation permits the impairment of ERK1/2-mediated cardiac hypertrophy without increasing cardiomyocyte death. The impact of ERK Thr188 phosphorylation on cardiomyocyte hypertrophy and cell survival was analyzed in isolated cells and in mice using the mutant ERK2 T188A , which is dominant-negative for ERK Thr188 signaling. ERK2 T188A efficiently attenuated cardiomyocyte hypertrophic responses to phenylephrine and to chronic pressure overload, but it affected neither antiapoptotic ERK1/2 signaling nor overall physiological cardiac function. In contrast to its inhibition of pathological hypertrophy, ERK2
T188A did not interfere with physiological cardiac growth occurring with age or upon voluntary exercise. A preferential role of ERK Thr188 phosphorylation in pathological types of hypertrophy was also seen in patients with aortic valve stenosis: ERK Thr188 phosphorylation was increased 8.5 ± 1.3-fold in high-gradient, rapidly progressing cases (≥40 mmHg gradient), whereas in low-gradient, slowly progressing cases, the increase was not significant. Because interference with ERK Thr188 phosphorylation (i) inhibits pathological hypertrophy and (ii) does not impair antiapoptotic ERK1/2 signaling and because ERK Thr188 phosphorylation shows strong prevalence for aortic stenosis patients with rapidly progressing course, we conclude that interference with ERK Thr188 phosphorylation offers the possibility to selectively address pathological types of cardiac hypertrophy.
MAPK | apoptosis | GPCRs C ardiac hypertrophy has been identified as an independent risk factor of diastolic dysfunction, heart failure, arrhythmias, and sudden death (1) . Various triggers initiate cardiac hypertrophy, but the type of trigger has been identified as decisive for an adaptive vs. a maladaptive outcome of cardiac hypertrophy. Whereas cardiovascular diseases such as hypertension, aortic stenosis, or myocardial infarction generally induce a pathological type of hypertrophy, chronic physical exercise or postnatal cardiac growth entail a compensatory and physiological type of hypertrophy. In contrast to physiological hypertrophy, pathological hypertrophy is characterized by accumulation of interstitial collagen and cell death, which both have been shown to contribute to increased cardiovascular risk (2) (3) (4) (5) . Therefore, it would be of great therapeutic interest to prevent pathological hypertrophy; however, such prevention requires a fine balance between inhibition of maladaptive and preservation of compensatory adaptive hypertrophy.
Hypertrophic stimuli are mediated via several intracellular signaling cascades that ultimately affect cardiac gene transcription. A central signaling cascade, which has been shown to promote the development of cardiac hypertrophy, is the mitogen-activated protein (MAP) kinase cascade consisting of the kinases rapid activation of fibrosarcoma (Raf), MAP/ERK kinase (MEK1/2), and ERK1/2. However, inhibition of ERK1/2-mediated hypertrophy using dominant-negative mutants or MEK inhibitors in isolated cardiomyocytes and in mice was accompanied by increased cardiomyocyte death (6) (7) (8) (9) (10) (11) (12) (13) . Therefore, to date, it has not been possible to exploit the potential of the ERK1/2 cascade as a therapeutic target in cardiac hypertrophy.
Here, we describe a possibility to selectively impair hypertrophic ERK1/2-mediated functions while leaving the antiapoptotic effects of ERK1/2 intact. We have previously discovered an ERK2
Thr188 autophosphorylation (ERK2 Thr188 corresponds to Thr208 in ERK1; subsequently referred to as ERK Thr188 phosphorylation) that appears to be essential for the induction of ERK1/2-mediated cardiac hypertrophy in response to various stimuli (14, 15) . Because inhibition of ERK1/2 is an effective strategy to prevent cardiac hypertrophy (6, 8, 12) , we aimed to investigate whether specific interference with ERK Thr188 phosphorylation had an effect on hypertrophy and on apoptosis in vivo. We further investigated the occurrence of ERK Thr188 phosphorylation in patients with different forms of aortic stenosis. Our data suggest a clinical relevance of this autophosphorylation and further indicate that interference with ERK Thr188 phosphorylation may be a selective therapeutic strategy in pathological ERK1/ 2-mediated cardiac hypertrophy.
Results

Interference with ERK
Thr188 Phosphorylation Attenuates ERK-Mediated Cardiomyocyte Hypertrophy but Not Cell Survival. First, we assessed whether interference with ERK Thr188 phosphorylation may be a strategy to attenuate cardiomyocyte hypertrophy without a simultaneous exaggeration of apoptotic cell death. For this study, we used an ERK2 mutant that cannot be phosphorylated at threonine 188, ERK2 T188A (T188A). Interestingly, overexpression of ERK2 T188A did not affect catalytic ERK activity, as monitored by MEK1/2-mediated phosphorylation of ERK1/2 at the socalled TEY motif [pERK1/2(TEY); Fig. S1 A-C] (6, 7). To exclude an overexpression artifact, we compared ERK2 T188A with similar expression levels of ERK2 wild-type (WT) [ERK2 T188T (T188T)] (Fig. S1D ).
ERK2
T188A overexpression in neonatal rat cardiomyocytes (NRCMs) significantly attenuated phenylephrine-induced cardiomyocyte hypertrophy, as assessed by incorporation of [ 3 H] isoleucine (Fig. 1A) and by cell size analysis (representative cells in Fig. 1B and quantification of cell size in Fig. S1E ) (16, 17) . Strikingly, ERK2 T188A did not enhance H 2 O 2 -induced apoptotic cell death, as determined by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) (Fig. 1C ) and procaspase-3 levels ( Fig. S1F) (18) (19) (20) . In contrast, overexpression of ERK2 T188T affected neither the hypertrophic (Fig. S1G ) nor apoptotic response of NRCMs (Fig. S1H) . Thus, expression of ERK2 T188A causes an efficient inhibition of cardiomyocyte hypertrophy but has no effect on apoptosis.
These results are particularly interesting because, as reported in the Introduction, inhibition of the catalytic ERK1/2 activity (e.g., by using the MEK1/2 inhibitor PD98059) attenuates cardiomyocyte hypertrophy in analogous assays (Fig. 1 D and E and Fig. S1I ) (21) . In contrast to ERK2 T188A , PD98059 leads to enhanced H 2 O 2 -induced apoptotic cell death ( Fig. 1F and Fig. S1J ).
To ensure that ERK2 T188A overexpression does indeed not affect apoptotic ERK1/2 signaling, we next analyzed its effect on apoptosis at endogenous expression levels. For these experiments, we used siRNAs to reduce endogenous ERK1/2 expression (Fig. 1G, middle blot) . Like ERK1/2 inhibition with PD98059 (Fig. S1K) , knock down of ERK1/2 activated the programmed cell death machinery, as evidenced by decreased procaspase-3 levels (Fig. 1G, upper blot and graph) . Accordingly, subsequent reexpression of WT ERK2 (T188T) reversed the apoptotic effect of the ERK1/2 knockdown (i.e., normalized the procaspase-3 expression levels; Fig. 1G ), confirming the antiapoptotic role of endogenously expressed ERK1/2. Interestingly, reexpression of ERK T188A normalized procaspase-3 expression levels as efficiently as did reexpression of ERK T188T (Fig. 1G ). Taken together, our experiments confirmed that ERK1/2, indeed, mediate both cardiomyocyte hypertrophy and survival in NRCMs. Our experiments further suggest that interference with ERK Thr188 phosphorylation-in contrast to catalytic inhibition of ERK1/2-might be a strategy to specifically target ERK-mediated hypertrophy without impairing ERK-mediated cell survival.
Inhibition of Hypertrophy by ERK2
T188A Does Not Exacerbate Apoptosis in Vivo. We then sought to confirm these findings obtained in isolated NRCMs in intact animals. For this study, we used FVB/N mice with transgenic cardiac expression of ERK2 T188A (T188A), and as controls, we used nontransgenic WT mice, as well as mice transgenic for ERK2 WT (T188T). ERK2 constructs were transgenically expressed at similar levels as the overall expression level of endogenous ERK1 and ERK2 (Fig. S2A ). These mice were subjected to chronic pressure overload stress induced by transverse aortic constriction (TAC) to induce hypertrophy and apoptosis (22) . Aortic pressure gradients were the same in the three groups: 70.7 ± 4.3 for WT, 72.5 ± 6.0 for ERK2 T188T , and 71.9 ± 2.6 for ERK2 T188A . Transgenic cardiac expression of ERK2 T188A significantly reduced the hypertrophic response to TAC compared with control mice (WT or T188T), as measured by heart weight-to-tibia length ratios ( Fig. 2A) , LV wall thickness (Table S1) , and cardiomyocyte size ( Fig. 2B and Fig. S2B ). Furthermore, echocardiographic analyses showed normal cardiac function in ERK2 T188A -expressing mice (Table S1 ). Sirius red staining of histological sections revealed that ERK2 T188A -overexpressing mice developed even less interstitial fibrosis in response to LV pressure overload ( Fig. 2 C  and D) . Interestingly, whereas ERK-mediated cardiac hypertrophy was efficiently inhibited in ERK T188A transgenic mice, the extent of apoptosis induced by TAC was comparable in all three genotypes ( Fig. 2 E and F) .
Thus, interference with ERK Thr188 phosphorylation permits efficient inhibition of TAC-induced cardiac hypertrophy and cardiac remodeling, with no adverse effects on cell survival and cardiac function.
ERK2
T188A Prevents Activation of Nuclear, Hypertrophic but Not Cytosolic Antiapoptotic ERK1/2 Signaling. To understand the mechanism that enables ERK2 T188A to distinguish between the different ERK functions (i.e., hypertrophy vs. apoptosis), we compared its effects on ERK1/2 target phosphorylation, looking at both cytosolic and nuclear targets. As ERK1/2 targets, which mediate the antiapoptotic effects of ERK1/2 and are, thus, primarily located within the cytosol, we investigated p90 ribosomal S6 kinase (p90RSK) and B-cell lymphoma 2-interacting mediator of cell death (BIM) (23) . As a nuclear target contributing to the transcriptional hypertrophic effects of ERK1/2, we analyzed ERK1/2-mediated phosphorylation of the nuclear ETS (E twenty-six)-like 1 transcription factor (Elk1) (24) . Both PD98059 and ERK2 T188A expression inhibited phenylephrine-induced phosphorylation of nuclear Elk1, but only PD98059 interfered with phenylephrineor H 2 O 2 -induced phosphorylation of cytosolic p90RSK and BIM (representative blots in Fig. 3 A and B; quantification in Fig. S3 A-F and G-L).
These experiments suggest that interference with ERK Thr188 phosphorylation (in contrast to inhibition of ERK1/2 activity by PD98059) selectively inhibits nuclear ERK targets, which may be explained by a prominent role of ERK Thr188 phosphorylation in nuclear accumulation of ERK1/2: (i) the ERK2 T188A mutant did not-unlike WT ERK2-accumulate within the nucleus in response to a hypertrophic stimulus (Fig. 3C) ; and (ii) WT ERK2 did not accumulate in the nucleus in response to H 2 O 2 ( Fig. 3C) , which activated ERK1/2 [i.e., pERK1/2(TEY)] but did not induce ERK Thr188 phosphorylation (representative immunoblots in Fig. 3D and quantification in Fig. S3 M-P).
T188A Does Not Affect Physiological Growth of the Heart. Even though cardiac hypertrophy is a risk factor for heart failure, therapeutic prevention of cardiac hypertrophy in patients should ideally impair neither the heart's normal postnatal growth nor its adequate growth in response to exercise (3, 4) . Therefore, we next investigated the influence of ERK2 T188A expression on physiological growth of the heart. For this analysis, we assessed cardiac growth (i) in mice until the age of 9 mo and (ii) in mice that exercised voluntarily in a running wheel for a period of 3 wk.
Postnatal cardiac growth up to 9 mo, as well as exercise-driven cardiac growth, was indistinguishable between ERK2 T188A -expressing and control mice (WT and T188T), as assessed by ventricular wall thicknesses (Fig. 4A) , cardiomyocyte size (representative sections in Fig. 4B and quantification in Fig. 4C ), and heart weight-to-tibia length or heart weight-to-body weight ratios, respectively ( Fig. S4 A and B) . Furthermore, echocardiographic analysis of heart function (Table S2 ) and histological analysis (representative sections in Fig. 4D and quantification in Fig. 4E ) did not reveal any pathological changes in ERK2 T188A -expressing mice at the age of 9 mo or after 3 wk of running-wheel exercise. Thus, interference with ERK Thr188 phosphorylation does not appear to interfere with physiological and healthy growth of the heart. In line with these findings, ERK Thr188 phosphorylation, which is necessary for ERK1/2-mediated cardiac hypertrophy (14) , was elevated only in TAC-operated mice but not in exercised mouse hearts (Fig. 4F ).
Differential ERK
Thr188 Phosphorylation in Patients with High-and LowGradient Aortic Stenosis. To further characterize the involvement of ERK Thr188 phosphorylation in cardiac hypertrophy, we analyzed septum samples of patients with aortic valve stenosis. These patients were subgrouped into high (≥40 mmHg) or low (<40 mmHg) transvalvular pressure gradients, which showed low or high degrees of interstitial fibrosis, respectively ( Fig. 5A ) (25) . Despite different transvalvular pressure gradients, both groups had a similar extent of hypertrophy at the time of surgery, as determined by echocardiographic analysis of heart weight (Table S3) , diastolic wall thickness (Table S3) , and histological analysis of cardiomyocyte cell area (Fig. 5B) . At the time of surgery, ejection fractions and aortic valve areas were also undistinguishable in both patient groups (Table S3) . Furthermore, canonical ERK1/2 activation (pERK[TEY]; Fig. 5C ) was similar in both patient groups. Interestingly, however, ERK Thr188 phosphorylation was >eightfold increased in patients with high transvalvular pressure gradients but not significantly (<twofold) enhanced in patients with low gradients (Fig. 5C ). Of these patients, 10/12 with high pressure gradients, but only 1/8 with low gradients, had a rapid course of disease ( Fig. 5D and Table S3 ). This indicates a close correlation between pressure gradients, rapid progression, and ERK Thr188 phosphorylation, even though the extent of ventricular hypertrophy at the time of surgery was similar in all patients (Table S3 , Fig. 5B , and Fig. S5 ). Thus, in contrast to similar canonical ERK1/2 activation in all samples, increased ERK Thr188 phosphorylation was seen specifically in the cases with rapid progression and high gradients (Fig. 5C ). This indicates that ERK Thr188 phosphorylation depends on the type of hypertrophic trigger and seems to be correlated with the rapidity of disease development (Fig. 5D ), rather than with its final extent of hypertrophy (Fig. S5) .
Taken together, the analyses of patients with aortic valve stenosis further substantiate the hypothesis that ERK Thr188 phosphorylation is not increased in all types of cardiac hypertrophy but is dependent on the type of hypertrophic trigger and is, in particular, associated with high pressure load in mice and with rapidly progressing forms of aortic stenosis in patients.
Discussion
Pathological hypertrophy is a key risk factor for myocardial infarction, arrhythmia, and sudden death, whereas physiological growth of the heart in response to exercise is generally accepted to be protective, i.e., to preserve or even improve heart function (1, 4, 26) . Although maladaptive hypertrophy involves cell death, collagen deposits, fibrosis, and ventricular stiffening, these hallmarks of pathological remodeling are absent in the "athlete's" heart (1, 27) . Although there is an ongoing debate whether heart failure-associated ventricular hypertrophy has a compensatory role in heart failure patients, evidence is increasing that inhibition of pathological hypertrophy may be beneficial (3, 14, 15, (28) (29) (30) .
On the molecular level, pathological cardiac hypertrophy is mediated by various proteins including, Gα q , extracellular signalregulated kinases, protein kinase C, Ca 2+ /calmodulin, and nuclear factor of activated T cells. Even though these proteins are associated with pathological hypertrophy, many of them also play vital roles in normal cardiomyocyte functions (4-7, 31, 32) . Therefore, it is a challenging but critical task to identify features within pathological hypertrophic signaling pathways that allow to specifically target maladaptive functions of candidate proteins.
The ERK1/2 cascade has been reported to be activated and to be involved in diverse instances of cardiac hypertrophy and heart failure including cardiomyopathies, both in rodents and humans, and has, thus, been considered as a putative therapeutic target in pathological hypertrophy (6, (33) (34) (35) . However, many mouse models point toward a pivotal role of ERK1/2 in the prevention of apoptotic cell death: cell death is significantly increased in mice with cardiac overexpression of dominant-negative Raf1, in mice treated with MEK1/2-inhibitors, and in ERK1 −/− ERK2 +/− mice (11, 12, 36) , whereas overexpression of constitutively active MEK1 increases cell survival (37, 38) . Therefore, inhibition of T188T (T188T) or phosphorylation-deficient ERK2 T188A (T188A) at the age of 8 wk (CON), at the age of 9 mo (9 MON), and afterERK1/2 activity is detrimental for the heart and, thus, cannot be used to target cardiac hypertrophy. Our present study identifies ERK Thr188 phosphorylation as a tool to differentiate between these distinct functions of ERK1/2 in the heart: increased cell death as a maladaptive and reduced hypertrophy as a potentially beneficial consequence of ERK1/2 inhibition. With the help of ERK2 T188A , the impact of ERK Thr188 phosphorylation on cardiomyocyte hypertrophy in vitro and in vivo was demonstrated. Expression of ERK2 T188A attenuated the hypertrophic responses of pathological stimuli such as phenylephrine, angiotensin II, isoprenaline, and chronic pressure overload (14, 15) . However, protective, antiapoptotic ERK1/2 signaling in vitro and in vivo (Fig. 1C and Fig. 2 E and F) , as well as cardiac function (Tables S1 and S2), were not disturbed by ERK2   T188A expression. Therefore, ERK2
T188A appears to display its dominant-negative effect on nuclear ERK1/2 signaling via dimerization with endogenous WT ERK1/2 and by retaining them within the cytosol. This hypothesis is supported by the following: (i) the ability of ERK2 T188A to dimerize with ERK2 (ref. 14 and Fig. S6 A and B) ; (ii) the ability of ERK2 to heterodimerize with ERK1 (ref. 15 and Fig. S6 A and B) ; (iii) the cytosolic retention of YFP-tagged WT ERK2 in the presence of ERK2 T188A (Fig. S6C) ; and (iv) earlier observations that both ERK dimerization and ERK Thr188 phosphorylation are required for nuclear accumulation (15, 39) .
Interestingly, ERK Thr188 phosphorylation may be controlled by β-arrestins, interaction partners of ERK1/2. Overexpression of β-arrestin2 prevented the interaction of ERK2 with Gβγ subunits, an interaction that is necessary to induce ERK2 Thr188 phosphorylation ( Fig. S6 F-I) did not interfere with physiological (postnatal or exercise-driven) growth of the heart, and even long-term interference with ERK Thr188 phosphorylation did not reveal any cardiac adverse effects (Fig. 4 and Table S2 ). However, because this mechanism appears to be of a general nature, it will be important to delineate it in more detail in both cardiac and noncardiac cells and tissues. The analysis of septal samples of patients with aortic valve stenosis further confirms that ERK Thr188 phosphorylation is a marker for pathological hypertrophy: ERK Thr188 phosphorylation was significantly increased in patients with high pressure gradients and with a rapid course of the disease (Fig. 5 C and D) .
Interestingly, in patients with aortic valve stenosis, we found a negative correlation for fibrosis and ERK Thr188 phosphorylation. Low-gradient patients had a significantly higher degree of interstitial fibrosis than those with high-gradient stenosis (Fig. 5A ), but ERK Thr188 phosphorylation was only significantly up-regulated in high-gradient patients (Fig. 5C ). This observation essentially excludes the possibility that up-regulation of ERK Thr188 phosphorylation in myocardial biopsies may originate from increased numbers or activation of cardiac fibroblasts attributable to increased interstitial fibrosis (42) . Further clinical studies should aim to delineate whether these differences in ERK Thr188 phosphorylation are simply attributable to the mechanical differences (gradient) or whether the two forms are different clinical entities.
Future studies will have to establish how these effects of ERK T188A may be therapeutically exploited. Although gene therapy with ERK T188A may be a possibility, it would seem most attractive to search for small molecule inhibitors that specifically interfere with ERK Thr188 phosphorylation. Because the antiapoptotic effects of ERK1/2 depend on their enzymatic/catalytic activity (Fig. 1F) , mechanistic prerequisites for ERK Thr188 phosphorylation may represent interesting strategies for specific interference with ERK Thr188 phosphorylation. ERK Thr188 phosphorylation is dependent on (i) dimerization of activated ERK1/2 and (ii) subsequent binding of Gβγ subunits to dimeric ERK1/2 (14, 15) . Thus, inhibition of ERK1/2 dimerization or inhibition of the ERK/Gβγ interaction might represent possibilities to specifically interfere with ERK Thr188 phosphorylation and, thus, with ERK1/2-mediated hypertrophy without affecting the antiapoptotic ERK1/2 signaling in the heart. To date, these approaches have been positively tested with overexpressed peptides and with mutant proteins in cardiomyocytes in vitro and/or in vivo and await molecular modeling of small molecule inhibitors (14, 15) . Such experiments will have to consider that ERK1/2 mediate a panoply of functions within the body and that such targeting strategies may interfere with pivotal ERK1/2 functions other than pathological hypertrophy.
Taken together, our results show that specific interference with ERK Thr188 phosphorylation permits differential targeting of distinct ERK1/2 effects (hypertrophy vs. cell survival), as well as of distinct types of hypertrophy (pathological vs. physiological). Selective occurrence of ERK Thr188 phosphorylation in patients with rapidly progressing, high-gradient aortic valve stenosis further suggests ERK Thr188 phosphorylation as a favorable target in pathological cardiac hypertrophy.
Materials and Methods
An expanded section on materials and methods is available in SI Materials and Methods.
Mice, Rats, and Cardiomyocytes. The generation of transgenic mice overexpressing ERK2 T188A (T188A) and ERK2 T188T (T188T) under the control of the mouse α-myosin heavy chain promoter was described previously (14) . For all experiments, male mice with an FVB/N background were used and as control isogenic WT FVB/N mice. Pregnant Sprague-Dawley rats were purchased from Janvier. NRCMs were prepared from left ventricles of 1-to 2-d-old Sprague-Dawley rats as described previously (14, 15, 43) . Care of the animals was performed in accordance with the Committee on Preparation of Neonatal Rat Cardiomyocytes, Cell Culture, and Adenoviral Infection. Neonatal rat cardiomyocytes (NRCMs) were prepared from left ventricles of 1-to 2-d old SpragueDawley rats as described previously (1-3). Briefly, after isolation left ventricles were subjected to multiple rounds of enzymatic digestion using collagenase type II (Worthington) or trypsin (Becton Dickinson). Nonmyocytes were removed from the cell suspension by a 1-h preplating step. The purity of the isolated NRCMs was analyzed by α-actinin and DAPI staining (>95% α-actinin-positive cells) (2) . Cardiomyocytes were cultured in Minimum Essential Medium Eagle (MEM) (Sigma) containing 5% (vol/vol) FCS (Biochrom), 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 350 mg/L NaHCO 3 , 30 mg/L 5-bromo-2′-deoxyuridine (BrdU) (Sigma), and 2 mg/L vitamin B 12 (AppliChem) at 37°C and 1% CO 2 . After 24 h, FCS concentration was reduced to 1% (vol/vol). Forty-eight hours after isolation, NRCMs were transduced with adenoviruses encoding for green fluorescent protein (GFP) (2), Flag-tagged or YFP-tagged murine WT ERK2 (T188T) (2), or Flag-or YFP-tagged phosphorylationdeficient ERK2 T188A (T188A) (2). For phenylephrine (PHE) treatment, cells were starved (24 h) after 24 h of adenoviral infection and then incubated with PHE (4 μM; 10 min or 24 h; Sigma). For induction of apoptosis, NRCMs were treated with hydrogen peroxide (H 2 O 2 ) (100-400 μM; AppliChem) for 1 or 4 h with or without preincubation with PD98059 (30 μM; 60 min; Calbiochem) as indicated. Analysis of apoptosis was performed by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay or by Western blot analysis of expression levels of procaspase-3 as described below.
cDNA Constructs. HA-tagged murine ERK2 (T188T) (1) and ERK2 T188A (T188A) (1), Flag-tagged murine ERK2 (T188T) (1) and ERK2 T188A (T188A) (1), YFP-ERK2 (T188T) (1), and Flagtagged β-arrestin2, β-arrestin2, and α 1B -adrenergic receptor (3) were subcloned into pcDNA3 vector (Invitrogen) for transient expression in eukaryotic cells. The correct sequence of all constructs was confirmed by DNA sequencing.
Cell Culture and Transfection of HEK293 and COS7 Cells. Human embryonic kidney 293 (HEK293) cells were transfected using the calcium phosphate precipitation method and cultured as described previously (1) . COS7 cells were transfected using the DEAE-dextran method and cultured as described previously (1, 2). Twenty-four hours after transfection, cells were serum starved. Assays were performed 40 h after transfection.
Transfection of siRNAs. For siRNA-mediated knock down of endogenous ERK1/2 expression, siRNAs were purchased from Dharmacon: ERK1 [(On-Target plus Smart Pool, Rat MAPK3 (50689)], ERK2 (sense: 5′-ACAUGGAGCUGGACGACUUUU-3′; antisense: 5′-AAGUCGUCCAGCUCCAUGUUU-3′), and scramble (On-Target plus Nontargeting siRNA#1). NRCMs (450,000 cells per well in 24-well plates) were transfected with the respective siRNAs using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. ERK1/2 expression levels were analyzed 48 h after transfection. ERK1/2 were detected by Western blot analysis 48 h after transfection.
Western Blot Analysis. NRCMs were lysed in lysis buffer containing 1% (vol/vol) Triton-X-100, 5 mM EDTA, 300 mM NaCl, 50 mM Tris (pH 7.4), 20 μg/mL soybean trypsin inhibitor, 0.4 mM benzamidine, 1 mM PMSF, 50 mM NaF, 5 mM Na 4 P 2 O 7 , 0.1 mM Na 3 VO 4 , and 0.002% (wt/vol) NaN 3 . Lysates were incubated for 25 min at 4°C and then centrifuged for 10 min (25,200 × g). Equal amounts of proteins from each lysate were separated by SDS/ PAGE and then electrotransferred onto PVDF membranes (Amersham; Hybond-P). Membranes were blocked with 5% (wt/ vol) fat-free milk dissolved in Tris-buffered saline with 0.1% (vol/vol) Tween-20 for 2 h, followed by incubation with primary antibody overnight at 4°C. The following primary antibodies were used: β-actin (1:10000; A5441; Sigma), phospho-B-cell lymphoma 2-interacting mediator of cell death (phospho-BIM) (Ser69) (1:1,000; no. 4581; Cell Signaling), procaspase-3 (1:1,000; no. 9665S; Cell Signaling), phospho-Elk1 (Ser383) (1:750; no. 9181S; Cell Signaling), phospho-ERK1/2(TEY) (1:1,000; no. 9101L, Cell Signaling), ERK1/2 (1:1,000; no. 9102, Cell Signaling; different batches), ERK2 (1:1,000; sc-153; Santa Cruz Biotechnology), phospho-ERK1/2(Thr188) (1), Flag (1:10,000; F3165; Sigma), Gβ (1:5,000; sc-378; Santa Cruz Biotechnology), HA (1:5,000; MMS-101R; Covance), phospho-p90RSK(Ser380) (1:1,000; no. 9341S; Cell Signaling). For detection of primary antibodies, peroxidase-conjugated secondary antibodies (1:5,000 to 1:10,000) and the Amersham ECL Plus Western Blotting kit were used. Immunoblot signals were quantified using ImageJ or Photoshop.
Coimmunoprecipitation Assays. Immunoprecipitation assays were performed as described previously (1, 2) . Briefly, cells were lysed in ice-cold lysis buffer [0.5% (vol/vol) Nonidet P-40, 150 mM NaCl, 25 mM Na 4 P 2 O 7 , 50 mM β-glycerol phosphate disodium salt, 2 mM EDTA, 2 mM EGTA, 25 mM Tris (pH 8.0), 10% (vol/ vol) glycerol, 50 mM NaF, 0.1 mM Na 3 VO 4 , 0.002% (wt/vol) NaN 3 supplemented with protease inhibitors (10 μg/mL soybean trypsin inhibitor, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride)]. After centrifugation (25,200 × g; 4°C; 15 min), the supernatant was incubated with anti-Flag antibodies bound to Protein A-Sepharose (GE Healthcare) for 2 h at 4°C. Coimmunoprecipitated HA-ERK2 or Gβ subunits were detected by immunoblot analysis using the indicated antibodies. Immunoblot signals were quantified by densitometric analysis, and signals were normalized to unstimulated Flag-β-arrestin2/HA-ERK2-, Flag-ERK2-, or Flag-ERK2/HA-ERK2-transfected cells, respectively. Only immunoblots with equal Flag-β-arrestin2 or Flag-ERK2 precipitation, respectively, were included in the analyses.
TUNEL Assay. For TUNEL staining, tissue sections (2 μm) were dewaxed and rehydrated, permeabilized with proteinase K (AppliChem), and then treated with RNase. Cultured NRCMs were seeded on poly-L-lysine-coated glass coverslips (1.6 × 10 5 cells per well in 24-well plates). After induction of apoptosis, cells were fixed with 4% (wt/vol) paraformaldehyde for 30 min at room temperature, followed by permeabilization with 0.1% (vol/ vol) Triton X-100 in 0.1% (wt/vol) sodium citrate for 7 min on ice. TUNEL assay on tissue sections and cultured cells, respectively, was then performed according to the manufacturer's protocol (no. 12156792910 or no. 11684795910; Roche) by incubation with the TUNEL reaction mixture for 60 min at 37°C in a dark, humidified chamber. For positive controls, tissue sections were preincubated with DNase I (Sigma). For negative controls, tissue sections were incubated with TUNEL reaction mixture lacking terminal transferase (TdT). Cell nuclei were counterstained with Hoechst33258 or propidium iodide (Sigma). Samples were analyzed by fluorescence microscopy (Leica; DM 4000B).
Caspase-3 Activity. Caspase-3 activity was analyzed using the Caspase-Glo 3/7 Assay kit (Promega). Frozen heart tissue was homogenized in lysis buffer containing 1% (vol/vol) Triton X-100, 5 mM EDTA, 300 mM NaCl, 50 mM Tris (pH 7.4), 20 μg/mL soybean trypsin inhibitor, 0.4 mM benzamidine, 1 mM PMSF, 50 mM NaF, 5 mM Na 4 P 2 O 7 , 0.1 mM Na 3 VO 4 , and 0.002% (wt/vol) NaN 3 and centrifuged for 10 min (25,200 × g). Protein concentration of the samples was adjusted to 0.2 mg/mL 50 μL of reaction reagent were added to 50 μL of sample in a white 96-well plate (Nunc) Confocal Microscopy of NRCMs. NRCMs were seeded on coverslips in six-well plates. Forty-eight hours after adenoviral transfection with YFP-ERK2 T188T (T188T) or YFP-ERK2 T188A (T188A), cells were treated either with H 2 O 2 (100 μM; 1h) or PHE (4 μM; 10 min) and were then fixed with 4% (wt/vol) paraformaldehyde for 10 min at room temperature. Cell nuclei were stained with DAPI. Samples were analyzed using a Leica TCS SP5 confocal microscope. DAPI was excited with a diode laser at 405 nm and measured between 430 and 453 nm. YFP was excited with the 488-nm line of an argon laser and measured between 550 and 620 nm. Images were taken and analyzed in blinded fashion. For actin staining, NRCMs were fixed and stained with Alexa Fluor488-labeled phalloidin. For the quantification of the crosssectional areas, 25 cells per group and experiment were analyzed by computerized pixel counting in blinded fashion.
Quantification of the Nuclear-to-Cytosolic Ratios of YFP-ERK2. COS7 cells were seeded on coverslips and transfected with the indicated cDNAs as described above. Cells were serum-starved 24 h after transfection. Forty hours after transfection, cells were stimulated with PHE (10 μM; 10 min) and subsequently fixed using paraformaldehyde (4% (wt/vol); 10 min; room temperature). Nuclei were stained with DAPI (700 ng/mL). For examination of nuclear-to-cytosolic ratios of ERK2 localization, a Leica TCS SP5 confocal microscope was used. YFP was excited using the 488-nm line of an argon laser, and fluorescence was measured between 530-620 nm. DAPI was excited with a diode laser at 405 nm and fluorescence was measured between 430 and 463 nm. To further exclude spillover of DAPI into the YFP channel, confocal pictures were recorded using the sequential mode option. Experiments were performed in blinded fashion and ImageJ software was used to quantify the nuclear-to-cytosolic ratios as described previously (1, 2).
Transverse Aortic Constriction. At the age of 8 wk, male WT (FVB/ N background), ERK2
T188T (T188T), and ERK2 T188A (T188A) transgenic mice were subjected to transverse aortic constriction (TAC) using a 27-gauge needle to induce chronic left ventricular (LV) pressure overload as described previously (1) . Mice were anesthetized intraperitoneally with pentobarbital (40 mg/kg body weight). Carprofen (4 mg/kg body weight) was given s.c. for postoperative analgesia. Before TAC and 6 wk after TAC, echocardiography was performed, and mice were killed. Hearts were then isolated for biochemical, histological, and heart weight analyses.
Voluntary Cage Exercise. At the age of 8-10 wk, individual male WT (FVB/N background), ERK2
T188T (T188T), and ERK2 T188A (T188A) transgenic mice were housed in a cage (26 × 22.5 × 36.5 cm) with free access to a 25-cm-diameter running wheel with a 4.5-cm-wide running surface equipped with a digital magnetic counter that is activated by wheel rotation (Tecniplast). Daily running distances were recorded for each animal throughout the exercise period of 3 wk. The average running distance was 10.2 ± 0.6 km/d. Before and 3 wk after exercise, echocardiography was performed. Mice were killed, and hearts were isolated for biochemical, histological, and heart weight analyses.
Echocardiography. Mice were anesthetized intraperitoneally with pentobarbital (35 mg/kg body weight). Transthoracic echocardiograms were performed in a blinded manner using the Vevo700 or Vevo2100 high-resolution imaging systems (VisualSonics) and a 30-MHz probe. Values for end-diastolic septal and posterior wall thicknesses as well as end-diastolic and -systolic internal diameters were obtained from 2D M-mode images in the short axis view at the proximal level of the papillary muscles. Analysis of Patients with Aortic Valve Stenosis. Twenty patients were regularly followed from moderate (aortic valve area, 1.0-1.5 cm 2 ) to severe symptomatic aortic valve stenosis (aortic valve area, <1.0 cm 2 ) and underwent transthoracic echocardiography at least 1 y before and within 3 wk before aortic valve replacement.
Rapid progress of the stenosis was defined as an increase in peak aortic flow velocity ≥0.3 m·s −1 y −1 (5). Echocardiography was performed using the Vivid 7 System (GE Vingmed Ultrasound) with a 3.5-NHz transducer. LV end-diastolic and endsystolic dimensions, as well as end-diastolic thickness of the septum and posterior wall, were measured from M-mode parasternal LV long axis images. EF was calculated using the modified Simpson's biplane method. Continuous-wave Doppler recordings for assessing maximal aortic valve velocity were derived using the multiwindow interrogation. Peak aortic valve and LV outflow tract velocities and gradients were measured using continuousand pulsed-wave Doppler. Aortic valve area was calculated by the continuity equation according to American Heart Association and European Society of Cardiology guidelines (4, 6, 7) . Patients were grouped in high-gradient (≥40 mmHg; n = 12) and low transvalvular pressure gradient (<40 mmHg; n = 8) (6, 7) . In patients with low-flow/low-gradient stenosis (reduced EF; gradient, <40 mmHg; aortic valve area, <1.0 cm 2 ), the severity of aortic valve stenosis (AS) may be particularly difficult to assess because compromised aortic valve opening may be attributable to either significant valvular stenosis or to poor LV function. In such cases, a low-dose dobutamine stress echo was performed to confirm true severe stenosis. Only patients with a true stenosis were included. Biopsy samples of the basal septum were taken during aortic valve replacement. For the determination of myocyte size, cross-sectional areas of 80 individual cells per patient were analyzed by computerized pixel counting. Informed consent was obtained from all patients. The study was reviewed and approved by the ethics committee of the Medical Faculty of the University of Würzburg and was conducted according the principles outlined in the Declaration of Helsinki.
Statistical Analysis. Statistical significance was evaluated by oneway ANOVA using GraphPad Prism software. Bonferroni's test was used as post hoc test, with P < 0.05 regarded as significant. All data are shown as means ± SEM or as indicated. Individual experiments were reproduced at least three times. All histological and echocardiographic evaluations were performed in a blinded fashion. Quantification of phospho-Elk1 (n = 9 experiments; *P < 0.05 vs. all other conditions) (A); phospho-p90RSK(Ser380) (n = 6; *P < 0.001 vs. unstimulated controls) (B); phospho-BIM(Ser69) (n = 5; *P < 0.001 vs. unstimulated controls) (C); phospho-Elk1 (n = 6) (D); phospho-p90RSK(Ser380) (n = 6; *P < 0.001 vs. unstimulated controls) (E); phospho-BIM(Ser69) (n = 4; *P < 0.05 vs. unstimulated controls) (F); phospho-Elk1 (n = 5; *P < 0.01 vs. all other conditions) (G); phospho-p90RSK (Ser380) (n = 6; *P < 0.05 vs. all other conditions) (H); phospho-BIM(Ser69) (n = 8; *P < 0.01 vs. all other conditions) (I); phospho-Elk1 (n = 8) (J); phospho-p90RSK (Ser380) (n = 6; *P < 0.01 vs. all other conditions) (K); and phospho-BIM(Ser69) (n = 5; *P < 0.05 vs. all other conditions) (L). (M-P) Immunoblot quantification of ERK1/2 phosphorylations [i.e., pERK(Thr188) and pERK(TEY), respectively] of mock-transfected NRCMs stimulated with PHE (4 μM; 10 min) or H 2 O 2 (100 μM; 60 min). *P < 0.05 (n = 4-8). Fig. S4. (A and B) Analysis of heart weight-to-tibia length of 9-mo old mice (9 MON) (A) and heart weight-to-body weight ratios of mice after 3 wk of voluntary running wheel exercise (RUN) and 11-wk-old control mice (CON) (B) (n = 7-22). *P < 0.05 vs. CON. (C) Quantification of pERK(TEY) phosphorylation in heart lysates of 8-wk-old WT mice, of mice after 3 wk of voluntary running wheel exercise (RUN), or after 6 wk of pressure overload (TAC) (n = 5; P < 0.01 vs. all other conditions). A representative immunoblot is shown in Fig. 4F . Values in parentheses are ±SEM. bpm, beats per minute; IVS, interventricular septal; LVID, LV internal dimension; LVPW, LV posterior wall. *P < 0.001 vs. TAC WT and TAC T188T. Table S2 . Echocardiographic characteristics of 9-mo old mice and mice after 3 wk of voluntary running wheel exercise Values are means (SD) unless indicated otherwise. *P < 0.05 vs. severe aortic stenosis high-gradient.
